This study, known as TOPCAT (Treatment Of Preserved Cardiac function heart failure with an Aldosterone anTagonist), is being sponsored by the National Institutes of Health. The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy, spironolactone, in reducing all-cause mortality in patients who have heart failure with preserved systolic function. The primary endpoint is a composite of cardiovascular mortality, aborted cardiac arrest or hospitalization for the management of heart failure.
Approximately 3515 adults with heart failure and left ventricular ejection fraction of at least 45% will be recruited from over 200 sites in the United States. The Reading Hospital has completed enrollment in the TOPCAT study, but it continues to conduct follow-up visits with the patients who are already enrolled in the study.
For more information, please call the Clinical Trials Office at 610-988-4308 or visit clinicaltrials.gov.